Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Bolsters Management Team

Canada NewsWire July 17, 2017

Medicenna Announces March 31, 2017 Year End Results

Canada NewsWire June 16, 2017

Medicenna's Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology

Canada NewsWire June 8, 2017

Medicenna Therapeutics Corp. Opens the Market

Canada NewsWire May 25, 2017

Medicenna Therapeutics Opens the Market

Canada NewsWire May 25, 2017

Medicenna Strengthens Patent Portfolio for its Lead Clinical Candidate, MDNA55

Canada NewsWire April 27, 2017

Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017

Canada NewsWire April 20, 2017

Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial

Canada NewsWire April 13, 2017

Medicenna BioPharma Announces Strategic Collaboration with MD Anderson Cancer Center to Advance Next Generation Empowered Cytokines™

Canada NewsWire March 16, 2017

Medicenna shares resume trading under the symbol "MDNA"

Canada NewsWire March 8, 2017

IIROC Trading Resumption - AFCC; BTRU; LMC; MDNA; PGZ

Canada NewsWire March 7, 2017

IIROC Trade Resumption - Medicenna Therapeutics Corp.

Newsfile March 7, 2017